Strategies in FY 23 is to bring focus to our new launches

The Sysmex Way, the corporate philosophy of the Sysmex Group, defines our mission of shaping the advancement of healthcare.

Sysmex operates in the healthcare domain, which continues to evolve and develop, constantly changing its form as new needs are created by advances in science and society. Within the healthcare domain, the value of diagnostics is also increasing.

The Indian market is diverse at the level of economy, languages, and healthcare systems. Expanding and advancing our business foundation is the core of Sysmex’s strategy for India.

Sysmex analyzers have been the preferred choice and used by pathology labs since 1993, the year in which Sysmex started selling their quality products in India thru its distribution network. Over the years and with advance quality products, Sysmex customer base and acceptance increased in India many folds.

Since 2013, gradually, Sysmex India has started offering direct sales and support in the urinalysis, hemostasis, and flow cytometry segments of in vitro diagnostics (IVD). From April 2019, Sysmex also commenced direct sales and support in the fields of hematology, anticipating further business expansion in line with India’s economic growth, increasing population, and progress on healthcare infrastructure.

Sysmex is the market leader in the hematology field, and we are constantly improving and innovating so that in the coming years we will be ready to take a major step toward Make in India. In the past few years, we have grown considerably in the field of urinalysis and are aiming to establish ourselves as market leaders in this field, and we take pride in the fact that we are already established as the numero uno market position in the field of hematology.

In line with this aim, Sysmex started investing in quality human resources in India. By start of FY 2023, total Sysmex employee strength in India will be 220+ and will continuously increase with increased business need.

While we have achieved a lot, there is still a lot more to do. As a new year heralds new beginning, in FY 2023, we aim to:

• Create innovative diagnostic values as a top IVD company.
• Expand and achieve high growth through proactive investment in the key fields of our conventional IVD domain in the fields of hematology, urinalysis, and hemostasis.
• Introduce new business to achieve dynamic growth via the launch of clinical flow cytometry solutions and life sciences like XF-1600 (multi color flow cytometry analyzer), PS-10 (flow cytometry sample preparation system), FISH probes, and NGS products.
• Enrich the talent portfolio, which contributes to strategy execution, and creates an attractive climate that leverages diverse talent.

One of our key strategies in FY 23 is to bring focus to our new launches. We are a global leader in multiple IVD categories including hematology, urinalysis, and hemostasis and a new entrant in automation workflow. Sysmex now is introducing a next level of automation of flow cytometry. Our flow cytometry system comprises the PS-10 sample preparation system, the Rotolavit-II-S automatic cell washing centrifuge, the XF-1600 flow cytometer, the Abs portfolio, ancillary reagents, and the VenturiOne data analysis software. With this, highly trained operators are no longer needed and can save their hours spent manually pipetting, thereby using their valuable time for more complex analytical activities with Sysmex’s next level of automation of flow cytometers.

Sysmex India continuously gives back to society through corporate social responsibility and has cultivated a culture of sustainability at its Mumbai corporate office and Baddi manufacturing plant. At Sysmex, sustainability is associated with our organization’s holistic approach, which takes everything into account, from manufacturing to logistics to customer service. Sysmex India will always continue its endowment toward society and nature.